Healthcare / BiotechnologyASX
$0.15
-0.01 (-6.06%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-45.2M · quality 72.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$81M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-246.4%
↓Gross Margin
86.3%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+47.4%
FCF CAGR
—
FCF margin
-100219.9%
FCF / Net income
1.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $65800.0 · net income $-58.7M · FCF $-65.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $65800.00 | $65800.00 | $46760.00 | $79224.00 | $20550.00 |
| Net Income | $-58.7M | $-58.7M | $-51.9M | $-39.2M | $-34.3M |
| EBITDA | $-58.5M | $-58.5M | $-51.9M | $-39.2M | $-34.0M |
| EPS | -0.20 | -0.20 | -0.18 | -0.16 | — |
| Gross Margin | 86.3% | 86.3% | 59.7% | -81.4% | -382.4% |
| Operating Margin | -99077.7% | -99077.7% | -128397.1% | -60575.7% | -211146.6% |
| Net Margin | -89138.6% | -89138.6% | -111013.7% | -49542.5% | -166896.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Current Ratio | 1.30 | 1.30 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-65.9M | $-65.9M | $-45.2M | $-32.2M | $-35.0M |
| Returns | |||||
| ROE | -246.4% | -246.4% | -96.7% | -92.8% | -43.8% |
| Valuation | |||||
| P/B | 1.91 | 1.91 | 5.20 | 6.16 | 6.11 |
| Growth & Yield | |||||
| Revenue Growth | 40.7% | 40.7% | -41.0% | 285.5% | — |
| EPS Growth | -11.6% | -11.6% | -10.0% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-49.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.18 → -0.20
Residual
-49.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.